CRNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-03-30), Crinetics Pharmaceuticals's share price is $34.73. Crinetics Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.85. Hence, Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
Crinetics Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.72. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.85.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -7.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -8.90% per year.
During the past 9 years, Crinetics Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was -5.10% per year. The lowest was -68.10% per year. And the median was -12.05% per year.
The historical data trend for Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
- | - | - | - | - |
Crinetics Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 34.73 | / | -2.847 | |
= | N/A |
Crinetics Pharmaceuticals's Share Price of today is $34.73.
Crinetics Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Crinetics Pharmaceuticals (NAS:CRNX) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Dana Pizzuti | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Richard Scott Struthers | director, officer: See Remarks | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Jeff E. Knight | officer: Chief Operating Officer | CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
Marc Wilson | officer: See Remarks | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Stephen F. Betz | officer: Chief Scientific Officer | 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121 |
James Hassard | officer: Chief Commercial Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Stephanie Okey | director | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Alan Seth Krasner | officer: Chief Medical Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Vivaldi Coelho Rogerio | director | 225 SECOND AVENUE, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Caren Deardorf | director | C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Ajay Madan | officer: Chief Development Officer | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
From GuruFocus
By GuruFocus News • 01-31-2025
By Marketwired • 02-27-2025
By Marketwired • 02-24-2025
By GuruFocus News • 02-10-2025
By GuruFocus News • 02-28-2025
By Marketwired • 01-10-2025
By GuruFocus News • 02-07-2025
By Marketwired • 02-06-2025
By GuruFocus News • 01-11-2025
By Marketwired • 01-10-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.